International Conference on Pharmaceutical Chemistry September 05-07, 2016 Frankfurt, Germany

Prof. Dr. Kreuter studied pharmacy from 1968 to 1971 at the Philipps-University Marburg, Germany. He did his Ph.D. from 1972 to 1974 at the Eidgenössische Technische Hochschule Zürich (ETH, Swiss Federal Institute of Technology) under the supervision of Prof. P. Speiser. His doctoral thesis was honoured with the ETH-Medal. He received his habilitation (D.Sc.) in 1982 at the ETH. In 1977 he worked as a postdoc with Prof. T. Higuchi in Lawrence, Kansas, U.S.A. and in 1979 with Prof. W. I. Higuchi in Ann Arbor, Michigan, U.S.A. In 1983 he was a guest professor at the University of Wisconsin, Madison, U.S.A. 1984 he became associate professor in pharmaceutical technology at the Johann Wolfgang Goethe-University in Frankfurt. Simultaneously he was offered the position of a full professor in pharmaceutical technology in Vienna but remained in Frankfurt. In 1990 he became full professor in Frankfurt. Twice he was dean, 1988/89 and 1997/98. In addition, from 1987 to 1990 he was Governor of the Controlled Release Society. He is recipient of the APV-Price 1981, the PPD Award of the Japanese Society of Powder Technology 2009, the Takeru and Aja Higuchi Honorary Lecture Award of the Japanese Academy of Pharmaceutical Sciences 2010, the Best Paper Award and the Most Cited Paper Award of the European Journal of Pharmaceutics and Biopharmaceutics in 2000 and in 2012, respectively, and the Jorge Heller Outstanding Paper Award of the Journal of Controlled Release 2009.

His research areas include drug-targeting, nanoparticles, drug transport across the blood-brain barrier using nanoparticles, microspheres, trans-dermal transport, polymeric drug delivery systems, adjuvants for vacccines, solid solutions, stability testing by microcalorymetry, and container materials. He has over 300 publications.

Wei Zhang, PhD Professor and Director of the Center for Green Chemistry Department of Chemistry University of Massachusetts Boston

Chemistry

Wei Li, Ph.D. Professor and Faculty Director of Instrument Facility University of Tennessee Health Science Center 881 Madison Avenue, room 561 Memphis, TN 38163 901-448-7532

Instrument Facility

Hiroshi Maeda is a world renowned expert in macromolecular therapeutics. He created the world first polymeric-conjugate drug, SMANCS, approved for treatment of hepatoma in Japan. Consequently, he discovered the concept of EPR effect of macromolecular-drugs, ubiquitous mechanism for solid tumor selective targeting of polymeric drugs. He received MS, University of California, Devis, Fulbright student, Ph.D., M.D., Tohoku University. He published more than 450 papers in reputed journals. He was awarded Lifetime-Achievement-Award at Royal-Pharmaceutical-Society, Princess-Takamatsu-Award in Cancer Research, Tomizo-Yoshida-Award, highest award of Japan-Cancer-Assoc., and also selected as most cited influential scientist in pharmacology by Thomson Reuters 2014, and H-index of 89.

His key areas of research includes concept of EPR effect of macromolecular-drugs, ubiquitous mechanism for solid tumor selective targeting of polymeric drugs. He created the world first polymeric-conjugate drug, SMANCS, approved for treatment of hepatoma in Japan

Frank M. Boeckler received his Ph.D. in Medicinal Chemistry from the University of Erlangen (Germany) in 2004 under supervision of Prof. Peter Gmeiner. He is specialized in computational chemistry and drug design, ranging from QM methods to in silico screening. In 2006, he joined Prof. Sir Alan R. Fersht at the MRC Center for Protein Engineering in Cambridge/UK as Marie Curie fellow and discovered there p53 mutant stabilizers as potential new cancer therapeutics. While working in Cambridge at the interface of experiment and theory, he focused on molecular biology and biophysics. In 2008, he was appointed as Professor (W2tt) for Bioanalytics at Ludwig-Maximilians University (LMU) Munich. In 2010, he moved to Eberhard Karls University Tubingen as Professor for Medicinal Chemistry/Drug Design, where he now heads the Laboratory for Molecular Design & Pharmaceutical Biophysics. Since 2014, he is also member of the Center for Bioinformatics Tubingen. He received several awards, including the Klaus-Grohe Award in Medicinal Chemistry, the Research Award of the Dornhecker Foundation and the PHOENIX Pharmazie-Wissenschaftspreis. In 2014, he was announced to be runner-up for the EFMC Prize for a Young Medicinal Chemist in Academia. His work is dedicated to understanding molecular interactions, particularly -hole bonding effects, as the foundation for chemical biology and drug research and to apply theoretical, chemical, biological, structural and biophysical methods to cancer research, particularly, for targeting the human kinome and the extensive p53 network.

• Understanding molecular interactions particular focus is halogen bonding, an innovative, bifunctional interaction. In drug research by generating tools, models, strategies and concepts for molecular design and fragment-based screening. Diversity-optimized and target-focused halogen-enriched fragment libraries (HEFLibs), use medicinal chemistry in combination with structural biology and computational chemistry for lead optimization of HEFLibs. • Develop and optimize biophysical and computer-aided techniques for screening, innovative assay formats, based on semi-automated titration, magnetic beads, and solid-phase synthesis by plate-spotting. With DEKOIS2.0, we have established tools for benchmarking of virtual screening strategies. • Extending the idea of molecular design to structured therapeutic peptides, developing a chemical tool-kit that can be used for selecting antibody-like, structured peptides, such peptides will be useful for therapeutic, diagnostic, analytical procedures, because they can be easily functionalized or linked to proteins, ligands, materials, radioisotopes, etc. • He is particularly interested in innovative therapeutic concepts in oncology, including individualized therapy und novel targets: e.g. p53 mutant rescue and therapeutic intervention in the p53 pathway; studying the paradigm of molecular chaperones for protein-(mis)folding diseases, targeting protein-protein interactions, kinase polypharmacology, epigenetic targets, etc.

Asunción Barbero was born in Burgos, Spain. She studied Chemistry at the University of Valladolid, and received her PhD degree at the same university working with Prof. Pulido. She joined Prof. Ian Fleming’s group at the University of Cambridge as Marie Curie fello for two years working in the study of stereocontrol in organic synthesis using silicon chemistry. She came back to Valladolid as Assistant Professor, was promoted to Associate Professor in 2001 and obtained the spanish habilitation to full Professor in 2012. In 2013 she was appointed as Coordinator of the Grade of Chemistry of the University of Valladolid. She has co-authored around 50 international scientific publications and has delivered several invited and plenary lectures. Her current interests include the study of the silyl-cupration of multiple bonds and its application to the synthesis of natural and related products.

Organic synthesis, synthesis of heterocycles, Organometallic synthesis, Synthesis of carbocycles, synthesis of natural products

Carlos Feleder was selected by the Italian Ministry of Health to review grant applications for biomedical research. He reviews grants in the fields of neuroscience, immunology, and endocrinology. Dr. Feleder servers as a Principal Investigator at the Albany Center for Computational Nano-Neuroscience at The State University of New York. He has done his M.D. from School of Medicine, University of Buenos Aires, Buenos Aires, Argentina and completed his PhD. from The Frauenklinik fur Experimentelle Endokrinologie, University George-August, Gottingen, Germany; and Department of Physiology, School of Medicine, University of Buenos Aires, Argentina

Dr. Feleder has a long-standing interest in uncovering the mechanisms underlying the body's response to immune challenges, i.e., how the central nervous system controls the physiologic functions that protect the body from the harmful effects of infectious agents. In 2008, Dr. Feleder was awarded a three year research grant totaling $231,000 from the National Institutes of Health (NIH) to study the effects of the spleen in managing fever.

Dr Laurent Désaubry is a CNRS research director in the University of Strasbourg in France (website: http://desaubry.u-strasbg.fr/) and professor at Tianjin University of Science and Technology (TUST) in China. He is currently editor and board member of Frontiers in Chemistry, Medicinal Chemistry and Advances in Oncology Research and Treatments. In 1992, he received a Ph.D. degree in medicinal chemistry from Strasbourg University. From 1992 to 1996, he worked as a postdoctoral fellow at SUNY at Stony Brook, USA. He made another post-doctoral internship in Prof. Pierre Chambon’s laboratory before to get a CNRS Research Senior Scientist at the University of Strasbourg-CNRS. He was promoted CNRS research director (corresponds to full professor) in 2014, and became also professor at TUST in 2015.

Medicinal Chemistry and Advances in Oncology Research and Treatments

Dr. Bhargava Karumudi is a research specialist at University of Illinois, Chicago in the field of medicinal chemistry. He has completed his postdoctoral in medicinal chemistry in 2014 at University of Illinois.

Organic Synthesis/Medicinal Chemistry, Chemical Biology, Chemistry of natural products with interesting biological activity, Natural products drug discovery, developing new probes to explore promising drug targets/photoaffinity labeling, LC-MS/MS.

Praveen S Hiremath is currently working as a Principal Scientist at Pharmaceutics International Inc Pii. He has completed Masters and doctoral studies and PhD in Pharmaceutics. Dr. Hiremath has worked in renowned Pharmaceutical companies like Astra Zeneca and Ranbaxy. Also he has Postdoctoral experience in Pharmaceutical drug delivery and formulation from Western University of Health Sciences, California, USA. Dr. Hiremath has published several research articles in peer reviewed international journals. He has extensively presented his research at international conferences/symposiums. Dr. Hiremath has been an invited speaker at international conferences. He has been invited to edit books in Pharmaceutical formulation and technology. Dr. Hiremath serves on editorial board of Journal of Bioequivalence and Bioavailability, Journal of Bioanalysis and Biomedicine and Research in Pharmaceutical Biotechnology. He is a full member of Sigma Xi Scientific Research Society and member of AAPS.

Oral drug delivery Pharmaceutical formulation development Controlled release drug delivery systems Pharmaceutical intellectual property (IP) Lipid based drug delivery systems Pharmaceutical technology Quality-by-design (QBD).

Rafat M Mohareb is Head of Organic Chemistry department Faculty of Pharmacy Modern Sciences and Arts University Professor of Organic Chemistry at Department of Chemistry faculty of Science Giza, Egypt. He got his Ph D Organic Chemistry on 1984 Cairo university Full professor of Organic chemistry 1994 Visiting Professor at UC Berkeley University State of California USA from 1999- 2002 Visiting Professor At Kuwait University 19951996. He was Humboldt fellows in Germany in 1988, 1989, 1993, 1995, 1998, 2003, 2006 and 2009. He received the price of encouragement of research work from Egypt 1995. He published more than 108 Scientific publications in International journals. He Supervised more than 5 PhD M Sc Theses.

Synthesis of new heterocyclic compounds with different pharmaceutical uses. Heterocyclizations of some Human Hormones followed by application of the synthesized compounds in Medicinal chemistry.Synthesis new dyes and their applications towards different fabrics.Recently his research focused on synthesizing antitumor agents.

Dr. Sahar Ahmed is an Assistant Professor at the Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, KSA. She is Currently on leave from the Department of Medicinal Chemistry, Faculty of Pharmacy, Assiut University, Egypt. Dr. Ahmed received her B.Sc. from the Faculty of Pharmacy, Assiut University, Egypt, and then her M.Sc. From the same Faculty. She subsequently got her Ph.D. from the Faculty of Pharmacy, University of Alberta, Canada in 2010 under the supervision of Dr. K. Kaur followed by one year of a postdoc at the same Faculty. She has participated in many international conferences and published 15 publications in international journals and one chapter book.

Her research areas include Organic Synthesis/Medicinal Chemistry, and Cancer Targeting Peptides.

Asunción Barbero was born in Burgos, Spain. She studied Chemistry at the University of Valladolid, and received her PhD degree at the same university working with Prof. Pulido. She joined Prof. Ian Fleming’s group at the University of Cambridge as Marie Curie fello for two years working in the study of stereocontrol in organic synthesis using silicon chemistry. She came back to Valladolid as Assistant Professor, was promoted to Associate Professor in 2001 and obtained the spanish habilitation to full Professor in 2012. In 2013 she was appointed as Coordinator of the Grade of Chemistry of the University of Valladolid. She has co-authored around 50 international scientific publications and has delivered several invited and plenary lectures. Her current interests include the study of the silyl-cupration of multiple bonds and its application to the synthesis of natural and related products.

Organic synthesis, synthesis of heterocycles, Organometallic synthesis, Synthesis of carbocycles, synthesis of natural products